Maria G. Elias

Liverpool, NSW 2170, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Human Group IIA Secreted Phospholipase A2 and the Prostate Cancer Tumor Microenvironment: Potential Mechanisms.

Human Group IIA Secreted Phospholipase A2 and the Prostate Cancer Tumor Microenvironment: Potential Mechanisms.

Journal: International journal of molecular sciences

Published: June 01, 2026

The innate immune mediator group IIA secreted phospholipase A2 modulates lipid droplet formation in prostate cancer cells.

The innate immune mediator group IIA secreted phospholipase A2 modulates lipid droplet formation in prostate cancer cells.

Journal: Frontiers in cell and developmental biology

Published: December 23, 2025

Chemotherapeutic Potential of Fluorouracil-Platinum (IV) Prodrugs Against Cisplatin-Resistant Colorectal Cancer Cells.

Chemotherapeutic Potential of Fluorouracil-Platinum (IV) Prodrugs Against Cisplatin-Resistant Colorectal Cancer Cells.

Journal: Chemistry (Weinheim an der Bergstrasse, Germany)

Published: November 13, 2025

Potent anticancer 5-fluorouracil platinum(IV) prodrugs.

Potent anticancer 5-fluorouracil platinum(IV) prodrugs.

Journal: Journal of inorganic biochemistry

Published: September 28, 2025

The Quest for Non-Invasive Diagnosis: A Review of Liquid Biopsy in Glioblastoma.

The Quest for Non-Invasive Diagnosis: A Review of Liquid Biopsy in Glioblastoma.

Journal: Cancers

Published: July 15, 2025

The anti-neoplastic potency of epoxy-substituted polyaromatic platinum(II) and platinum(IV) complexes against A549 lung cancer cells.

The anti-neoplastic potency of epoxy-substituted polyaromatic platinum(II) and platinum(IV) complexes against A549 lung cancer cells.

Journal: European journal of medicinal chemistry

Published: March 06, 2025

Targeting secreted PLA2 interactions with EGFR and vimentin to arrest prostate tumour growth.

Targeting secreted PLA2 interactions with EGFR and vimentin to arrest prostate tumour growth.

Journal: Cell death & disease

Published: February 07, 2025

Chemotherapeutic Potential of Chlorambucil-Platinum(IV) Prodrugs against Cisplatin-Resistant Colorectal Cancer Cells.

Chemotherapeutic Potential of Chlorambucil-Platinum(IV) Prodrugs against Cisplatin-Resistant Colorectal Cancer Cells.

Journal: International journal of molecular sciences

Published: June 12, 2024

Anticancer Effect of PtIIPHENSS, PtII5MESS, PtII56MESS and Their Platinum(IV)-Dihydroxy Derivatives against Triple-Negative Breast Cancer and Cisplatin-Resistant Colorectal Cancer.

Anticancer Effect of PtIIPHENSS, PtII5MESS, PtII56MESS and Their Platinum(IV)-Dihydroxy Derivatives against Triple-Negative Breast Cancer and Cisplatin-Resistant Colorectal Cancer.

Journal: Cancers

Published: May 31, 2024

Unveiling the chemotherapeutic potential of two platinum(IV) complexes in skin cancer: in vitro and in vivo Insights.

Unveiling the chemotherapeutic potential of two platinum(IV) complexes in skin cancer: in vitro and in vivo Insights.

Journal: Current research in pharmacology and drug discovery

Published: May 27, 2024

Platinum(IV) Prodrugs Incorporating an Indole-Based Derivative, 5-Benzyloxyindole-3-Acetic Acid in the Axial Position Exhibit Prominent Anticancer Activity.

Platinum(IV) Prodrugs Incorporating an Indole-Based Derivative, 5-Benzyloxyindole-3-Acetic Acid in the Axial Position Exhibit Prominent Anticancer Activity.

Journal: International journal of molecular sciences

Published: November 29, 2023

Enhanced potency of a chloro-substituted polyaromatic platinum(II) complex and its platinum(IV) prodrug against lung cancer.

Enhanced potency of a chloro-substituted polyaromatic platinum(II) complex and its platinum(IV) prodrug against lung cancer.

Journal: Chemico-biological interactions

Published: August 09, 2023

Showing 1-12 of 19

Last Updated: 09/26/2026